Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans-Reference-Cited by-同舟云学术

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Published:2011-08-31 Issue:7362 Volume:477 Page:99-102
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Breitbach Caroline J.,Burke James,Jonker Derek,Stephenson Joe,Haas Andrew R.,Chow Laura Q. M.,Nieva Jorge,Hwang Tae-Ho,Moon Anne,Patt Richard,Pelusio Adina,Le Boeuf Fabrice,Burns Joe,Evgin Laura,De Silva Naomi,Cvancic Sara,Robertson Terri,Je Ji-Eun,Lee Yeon-Sook,Parato Kelley,Diallo Jean-Simon,Fenster Aaron,Daneshmand Manijeh,Bell John C.,Kirn David H.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature10358.pdf

Reference30 articles.

1. Kirn, D. H. & Thorne, S. H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nature Rev. Cancer 9, 64–71 (2009)

2. Parato, K. A., Senger, D., Forsyth, P. A. & Bell, J. C. Recent progress in the battle between oncolytic viruses and tumours. Nature Rev. Cancer 5, 965–976 (2005)

3. Liu, T. C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101–117 (2007)

4. Vanderplasschen, A., Hollinshead, M. & Smith, G. L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78, 2041–2048 (1997)

5. Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B. & Smith, G. L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl Acad. Sci. USA 95, 7544–7549 (1998)

Cited by 448 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials;Vaccines;2024-09-03

2. Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy;Molecular Therapy: Oncology;2024-09

3. Translation of oncolytic viruses in sarcoma;Molecular Therapy: Oncology;2024-09

4. Clinical strategies with antibody–drug conjugates as potential modifications for virotherapy;Drug Discovery Today;2024-09

5. Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations;Current Oncology;2024-08-23